Niki Y, Watanabe S, Tamada S, Yoshida K, Miyashita N, Nakajima M
Antimicrob Agents Chemother. 1999; 43(6):1494-6.
PMID: 10348779
PMC: 89305.
DOI: 10.1128/AAC.43.6.1494.
Kita H, Matsuo H, Takanaga H, Kawakami J, Yamamoto K, Iga T
Antimicrob Agents Chemother. 1999; 43(5):1091-7.
PMID: 10223919
PMC: 89116.
DOI: 10.1128/AAC.43.5.1091.
Williams D, Hopkins S
Eur J Clin Microbiol Infect Dis. 1998; 17(6):454-8.
PMID: 9758292
DOI: 10.1007/BF01691582.
Kinzig-Schippers M, Fuhr U, Cesana M, Muller C, STAIB A, Rietbrock S
Antimicrob Agents Chemother. 1998; 42(9):2359-64.
PMID: 9736563
PMC: 105833.
DOI: 10.1128/AAC.42.9.2359.
Ball P, Tillotson G
Drug Saf. 1995; 13(6):343-58.
PMID: 8652079
DOI: 10.2165/00002018-199513060-00004.
Quinolones potentiate cefazolin-induced seizures in DBA/2 mice.
DE Sarro A, Zappala M, Chimirri A, Grasso S, De Sarro G
Antimicrob Agents Chemother. 1993; 37(7):1497-503.
PMID: 8395790
PMC: 188001.
DOI: 10.1128/AAC.37.7.1497.
The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes.
Spaldin V, Madden S, Pool W, Woolf T, Park B
Br J Clin Pharmacol. 1994; 38(1):15-22.
PMID: 7946932
PMC: 1364832.
DOI: 10.1111/j.1365-2125.1994.tb04316.x.
The quinolones in chronic bronchitis.
Davies B, MAESEN F, Teengs J, Baur C
Pharm Weekbl Sci. 1986; 8(1):53-9.
PMID: 3960693
DOI: 10.1007/BF01975481.
Fluorinated quinolones. A review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy.
Janknegt R
Pharm Weekbl Sci. 1986; 8(1):1-21.
PMID: 3515312
DOI: 10.1007/BF01975473.
Interaction between quinolones and caffeine.
STAIB A, Stille W, Dietlein G, Shah P, Harder S, Mieke S
Drugs. 1987; 34 Suppl 1:170-4.
PMID: 3481318
DOI: 10.2165/00003495-198700341-00035.
Pharmacokinetics of ofloxacin and theophylline alone and in combination.
Fourtillan J, Granier J, Saint-Salvi B, Salmon J, SURJUS A, Tremblay D
Infection. 1986; 14 Suppl 1:S67-9.
PMID: 3456985
DOI: 10.1007/BF01645203.
A clinically significant interaction between ciprofloxacin and theophylline.
Thomson A, Thomson G, Hepburn M, Whiting B
Eur J Clin Pharmacol. 1987; 33(4):435-6.
PMID: 3443151
DOI: 10.1007/BF00637645.
Respiratory infections: clinical experiences with the new quinolones.
Davies B, MAESEN F
Pharm Weekbl Sci. 1987; 9 Suppl:S53-7.
PMID: 3438151
DOI: 10.1007/BF02075261.
The use of quinolones in respiratory tract infections.
MAESEN F, Davies B, Geraedts W, Baur C
Drugs. 1987; 34 Suppl 1:74-9.
PMID: 3325259
DOI: 10.2165/00003495-198700341-00016.
Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Monk J
Drugs. 1987; 33(4):346-91.
PMID: 3297617
DOI: 10.2165/00003495-198733040-00003.
The future of new oral antibiotics including the quinolones.
Bergeron M
CMAJ. 1988; 138(1):35-42.
PMID: 3275479
PMC: 1267506.
Effects of enoxacin, ofloxacin and norfloxacin on theophylline disposition in humans.
Sano M, KAWAKATSU K, Ohkita C, Yamamoto I, Takeyama M, Yamashina H
Eur J Clin Pharmacol. 1988; 35(2):161-5.
PMID: 3191935
DOI: 10.1007/BF00609246.
Danger of interaction between ciprofloxacin and theophylline.
Bem J, Mann R
Br Med J (Clin Res Ed). 1988; 296(6629):1131.
PMID: 3132238
PMC: 2545536.
DOI: 10.1136/bmj.296.6629.1131.
Overview of clinical experience with ciprofloxacin.
Ball A
Eur J Clin Microbiol. 1986; 5(2):214-9.
PMID: 3013631
DOI: 10.1007/BF02013993.
Safety profile of ofloxacin: the Italian data base.
Koverech A, Picari M, Granata F, Fostini R, Toniolo D, Recchia G
Infection. 1986; 14 Suppl 4:S335-7.
PMID: 2950062
DOI: 10.1007/BF01661312.
